**投稿说明**

所有稿件必须通过投稿平台在线提交：http://www.editorialmanager.com/fzm

经过线上投稿的稿件将被审查是否符合发表条件，请在提交的同时确定该稿件在该时间点仅提交给FZM，而没有在任何地方发表、同时提交或已被其他地方接受发表。本刊希望作者能授权其中一人与本刊联系，处理与稿件有关的所有事宜。所有收到的稿件都会被正式确认。稿件提交后，编辑会初步审查所有提交的稿件是否适合进行正式审查。在此过程中，编辑还将检查稿件是否按照 “作者须知”和“国际医学期刊编辑委员会（ICMJE）关于在医学期刊上进行、报告、编辑和发表学术工作的建议"（见http://www.icmje.org/recommendations/）准备。原创性不足、有严重的科学或技术缺陷、或缺乏重要信息的稿件在进入正式的同行评审之前就会被拒绝。不太可能引起FZM读者兴趣的稿件也有可能在这个阶段被拒绝。

本刊采用“双盲”审稿模式，进行同行评议的审稿人的选择完全由编辑决定。编辑部的将根据审稿人的意见对稿件做出最终决定，从审稿人那里收到的意见和建议（接受/拒绝/修改稿件）会转达给相应的作者。作者需要对审稿人的意见进行逐点回应，并提交稿件的修订版，这个过程存在会重复进行的可能。

编辑部会对已接受出版的稿件进行语法、标点符号、印刷风格和格式方面的编辑。校对完成的电子版将被发送给通信作者，通信作者应在三天内返回更正后的样稿，在此期限之后收到的修改可能无法纳入。

**著作权标准**

作者的著作权只应基于对以下三个部分的实质性贡献。

1. 研究的概念和设计或数据的获取或数据的分析和解释。

2. 起草文章或针对重要的知识内容对其进行严格的修改

3. 最终批准将要发表的版本。

仅仅参与资金的获得或数据的收集并不能成为作者的理由，对研究小组的一般监督也不足以等同于成为作者的理由。每个贡献者应充分参与工作，对稿件内容的适当部分承担公共责任。命名贡献者的顺序应基于贡献者对研究和撰写稿件的相对贡献。一旦提交，未经所有贡献者的书面同意，不得改变顺序。本刊根据稿件的类型、范围和参与机构的数量，规定了稿件的最大作者人数（见下文）。如果作者人数超过这些限制，作者应提供理由。

**稿件贡献声明**

撰稿人应说明他们每个人对稿件的贡献。根据实际情况，说明可分为以下几类：概念、设计、知识内容的定义、文献检索、临床研究、实验研究、数据采集、数据分析、统计分析、稿件准备、稿件编辑和稿件审查。作者的贡献声明将与文章一起印刷。一位或多位作者应该对整个工作从开始到发表文章的完整性负责。

**利益冲突**

所有作者必须在文末表明他们与稿件的发表或稿件中提到的机构或产品可能存在的任何利益冲突。

**伦理声明**

对于使用人类或动物受试者的研究，试验的设计、进行和结果报告必须符合良好临床实践指南（如食品和药物管理局（FDA）监管的临床试验的良好临床实践（美国）或医学研究委员会的临床试验良好临床实践指南（英国））和/或世界医学协会（WMA）的赫尔辛基宣言。一般来说，我们建议遵循主要研究者的国家标准。如果作者对研究是否按照上述标准进行有任何疑问，必须明确提出所选择的实验方法的理由，并说明和证明适当的机构审查委员会（IRB，针对人类对象）和/或机构动物护理和使用委员会（IACUC，针对动物对象）对进行有疑问的研究给予的明确批准。

所有提交给本刊考虑发表的研究报告必须包括证明已从相关伦理委员会获得适当批准的声明。任何描述使用人类受试者的研究的稿件必须包括一份声明，确认该实验是在每个参与者的事先知情同意（书面或口头，视情况而定）下进行的。所有的个人信息必须在发表前进行匿名处理，除非有相关病人的明确同意记录。任何描述使用动物受试者的研究的稿件必须在材料和方法部分（或描述实验程序的文字）中声明，确认采取了所有适当的措施以减少疼痛或不适，并应提供动物护理的细节。

**知情同意书**

任何描述涉及人类的研究（临床研究和病例报告）的研究文章都应在标题页中明确说明所有参与人员（受试者或合法授权的代表）在研究纳入前都给予了知情同意（根据情况为书面或口头）。一般来说，FZM要求，任何和所有可能泄露研究对象身份的细节都应被省略或匿名化。在极少数情况下，如果研究对象的可识别信息对病例介绍至关重要，那么知情同意声明是绝对必要的，除非该对象已经死亡。此外，证明材料的副本应以PDF格式提供给FZM。

**表格**

- 表格应该是不言自明的，不应该与文本材料重复。

- 用阿拉伯数字对表格进行编号，按其在文中首次引用的顺序连续排列，并为每个表格提供一个简短的标题。

- 将解释事项放在脚注中，而不是标题中。

- 在脚注中解释每个表格中使用的所有非标准的缩写。

- 所有完全借用、改编和修改的表格都要获得许可，并在脚注中注明出处。

- 对于脚注，请使用以下符号，并按此顺序排列。\*, †, ‡, §, ||,¶ , \*\*, ††, ‡‡

- 表格及其图例应在参考文献之后的文本末尾提供。表格及其编号应在文本中的相关位置引用。

**图片**

- 以JPEG格式上传图片。上传时文件大小应在1024kb以内。

- 图应按照它们在文中首次被引用的顺序连续编号。

- 标签、数字和符号应清晰且大小一致。图的字体应足够大，以便在缩小到适合打印的栏目宽度后仍能辨认。

- 在显微照片中使用的符号、箭头或字母应与背景形成对比，并应以转移字体或以组织覆盖的方式整齐地标记，而不是用笔。

- 标题和详细的解释应基于插图的图例。

- 当提交图表、散点图或直方图时，还应该提供它们所依据的数字数据。

- 照片和图表应进行修剪，以去除所有不需要的区域。

- 如果使用个人的照片，必须附上使用该照片的书面许可。

- 如果数字已在其他地方发表，请注明原始出处，并提交版权持有人的书面许可，以便复制材料。这类数字的图例中应出现一个信用行。

- 插图的图例。用双倍行距打出或打印出插图的图例，用阿拉伯数字与插图对应。当使用符号、箭头、数字或字母来识别插图的部分时，在图例中识别并解释每一个符号。解释内部比例（放大率），并确定显微照片中的染色方法。

- 最后的数字用于印刷生产。在提交修改后的稿件时，发送清晰的、有光泽的、未装裱的彩色照片打印件，高度为4英寸，宽度为6英寸。不接受数码照片的打印稿。如果数字图像是唯一的图像来源，请确保图像的最低分辨率为300dpi或1800×1600像素的TIFF格式。本刊保留裁剪、旋转、缩小或放大照片至可接受尺寸的权利。

**清单**

**封面信**

- 由所有撰稿人签名

- 涉及到的以前的出版物/演讲

- 所涉及到的资金来源

- 利益冲突

**作者**

- 提供姓氏和名字，以及中间名的首字母（如适用）。

- 提供通信的作者，并提供电子邮件地址

- 根据指示，限制投稿人的数量

- 除标题页外，论文中不透露身份（例如，方法中的研究所名称，将以前的研究作为 "我们的研究"，图标上的名字，照片中的研究所名称等）

**文稿和格式**

- 双倍行距

- 四边的页边距为2.5厘米

- 底部有页码

- 标题页包含所有需要的信息

- 提供行文标题(不超过50个字符)

- 摘要页包含稿件的完整标题

- 提供摘要（原创文章的结构化摘要为250字，所有其他稿件的非结构化摘要约为150字，不包括致编辑的信）。

- 提供的关键词（三个或更多）

- 75-100字的介绍

- 标题为标题大小写（非全大写）。

- 文中引用的参考文献应在标点符号之后，用上标加方括号。

- 参考文献按照期刊的说明，标点符号要检查清楚

- 发送文章文件时不要留有 "修改痕迹"。

**语言和语法**

- 统一的美式英语

- 在标题、摘要、关键词和正文中首次使用时分别写出每个缩写的全称，除非是标准计量单位。从1到10的数字要拼出来

- 句子开头的数字要拼写出来

- 检查手稿中的拼写、语法和标点错误

- 如果引用的是品牌名称，请提供制造商的名称和地址（城市和州/国家）。

- 物种名称应使用斜体字

**表和图**

- 表和图以及文本中没有重复的数据

- 提供绘制图表所依据的实际数字

- 图片质量要好（彩色）。

- 表和图的编号为阿拉伯字母（非罗马字母）。

- 粘贴在照片背面的标签（不写名字）

- 提供图例（不超过40字）

- 维护病人的隐私（如果没有得到许可的话）

- 提供借用的数字/表格的信用说明

- 表格中使用的每个缩写的全称都需要写在脚注中

***Frigid Zone Medicine***

**Instructions for Authors**

|  |  |
| --- | --- |
| **General Information** | [Top](http://www.eusjournal.com/contributors.asp#top) |

*Frigid Zone Medicine* (*FZM*) is a peer-reviewed online journal with quarterly print on demand compilation of issues published. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional/subject-based repository. The official website is at: http://www.frigidzonemedicine.com. All manuscripts must be submitted on-line through the website (http://www.editorialmanager.com/fzm).

|  |  |
| --- | --- |
| **Scope of the Journal** | [Top](http://www.eusjournal.com/contributors.asp#top) |

This journal publishes articles on the latest research results and leading developments in the field of frigid-zone medicine, providing an international academic platform for the local and overseas researchers of related fields. It aims at building a qualified international medical bridge for academic communication and development, leading the academic study of frigid-zone medicine, promoting the basic and clinical research levels in frigid zones, and improving the academic impact of China in this field.

|  |  |
| --- | --- |
| **The Editorial Process** | [Top](http://www.eusjournal.com/contributors.asp#top) |

A manuscript will be reviewed for possible publication with the understanding that it is being submitted to *FZM* alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The journal expects that authors would authorize one of them to correspond with the Journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability for formal review. During this process, editors will also check if the manuscripts are prepared according to the Author Instructions and the “International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals” (The Requirements, at <http://www.icmje.org/recommendations/>). Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the readers of *FZM* are also liable to be rejected at this stage itself.

Manuscripts that are found suitable for publication in the Journal are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other’s identity. Every manuscript is also assigned to a member of the editorial team, who based on the comments from the reviewers takes a final decision on the manuscript. The comments and suggestions (acceptance/ rejection/ amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point by point response to reviewers’ comments and submit a revised version of the manuscript. This process is repeated till reviewers and editors are satisfied with the manuscript.   
  
Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within three days. It may not be possible to incorporate corrections received after that period. The whole process of submission of the manuscript to final decision and sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as ‘Ahead of Print’ immediately on acceptance.

|  |  |
| --- | --- |
| **Authorship Criteria** | [Top](http://www.eusjournal.com/contributors.asp#top) |

Authorship credit should be based only on substantial contributions to each of the three components mentioned below:

1. Concept and design of study or acquisition of data or analysis and interpretation of data;
2. Drafting the article or revising it critically for important intellectual content; and
3. Final approval of the version to be published.

Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors. The journal prescribes a maximum number of authors for manuscripts depending upon the type of manuscript, its scope and number of institutions involved (vide infra). The authors should provide a justification, if the number of authors exceeds these limits.

|  |  |
| --- | --- |
| **Contribution Details** | [Top](http://www.eusjournal.com/contributors.asp#top) |

Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided in following categories, as applicable: concept, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. Authors' contributions will be printed along with the article. One or more author should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as 'guarantor'.

|  |  |
| --- | --- |
| **Conflicts of Interest/ Competing Interests** | [Top](http://www.eusjournal.com/contributors.asp#top) |

All authors of must disclose any and all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.

|  |  |
| --- | --- |
| **Statement of Human and Animal Rights** |  |

For research studies using human or animal subjects, the trial’s design, conduct and reporting of results must conform to Good Clinical Practice guidelines (such as the Good Clinical Practice in Food and Drug Administration (FDA)-Regulated Clinical Trials (USA) or the Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials (UK)) and/or to the World Medical Association (WMA) Declaration of Helsinki. Generally, we suggest that the national standard of the lead investigator be followed. If authors have any doubt as to whether the research was conducted in accordance with the above standards, the rationale for the chosen experimental approach must be clearly presented, along with a statement and proof of explicit approval given by the appropriate Institutional Review Board (IRB, for human subjects) and/or the Institutional Animal Care and Use Committee (IACUC, for animal subjects) for conducting the doubtful aspects of the study.

All research reports that are submitted for consideration of publication in this journal must include statement(s) of proof that the appropriate approvals were obtained from the relevant IRB or research ethics committee. Any manuscript describing a study that used human subjects must include a statement that affirms the experiments were performed with prior informed consent (written or verbal, as appropriate) from each participant. All personal information must be anonymized prior to publication, unless a record of explicit consent from the involved patient(s) has been provided. Any manuscript describing a study that used animal subjects must include a statement in the Materials and Methods section (or text describing the experimental procedures) that affirms all appropriate measures were taken to minimize pain or discomfort, and details of the animals’ care should be provided.

***Tables***

* Tables should be self-explanatory and should not duplicate textual material.
* Number tables, in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title for each.
* Place explanatory matter in footnotes, not in the heading.
* Explain in footnotes all non-standard abbreviations that are used in each table.
* Obtain permission for all fully borrowed, adapted, and modified tables and provide a credit line in the footnote.
* For footnotes use the following symbols, in this sequence: \*, †, ‡, §, ||,¶ , \*\*, ††, ‡‡
* Tables with their legends should be provided at the end of the text after the references. The tables along with their number should be cited at the relevant place in the text

***Illustrations (Figures)***

* Upload the images in JPEG format. The file size should be within 1024 kb in size while uploading.
* Figures should be numbered consecutively according to the order in which they have been first cited in the text.
* Labels, numbers, and symbols should be clear and of uniform size. The lettering for figures should be large enough to be legible after reduction to fit the width of a printed column.
* Symbols, arrows, or letters used in photomicrographs should contrast with the background and should be marked neatly with transfer type or by tissue overlay and not by pen.
* Titles and detailed explanations belong in the legends for illustrations not on the illustrations themselves.
* When graphs, scatter-grams or histograms are submitted the numerical data on which they are based should also be supplied.
* The photographs and figures should be trimmed to remove all the unwanted areas.
* If photographs of individuals are used, their pictures must be accompanied by written permission to use the photograph.
* If a figure has been published elsewhere, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. A credit line should appear in the legend for such figures.
* Legends for illustrations: Type or print out legends for illustrations using double spacing, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one in the legend. Explain the internal scale (magnification) and identify the method of staining in photomicrographs.
* Final figures for print production: Send sharp, glossy, un-mounted, color photographic prints, with height of 4 inches and width of 6 inches at the time of submitting the revised manuscript. Print outs of digital photographs are not acceptable. If digital images are the only source of images, ensure that the image has minimum resolution of 300 dpi or 1800 x 1600 pixels in TIFF format. The Journal reserves the right to crop, rotate, reduce, or enlarge the photographs to an acceptable size.

|  |  |
| --- | --- |
| **Informed Consent** |  |

Any research article describing a study (clinical research and case report) involving humans should contain a statement in the title page clearly stating that all involved persons (subjects or legally authorized representative) gave their informed consent (written or verbal, as appropriate) prior to study inclusion. In general, *FZM* requires that any and all details that might disclose the identity of the subjects under study should be omitted or anonymized. In the rare situation that a study participant’s identifiable information is crucial to the case presentation, the statement of informed consent is absolutely necessary, unless the participant is deceased. In addition, a copy of any approval document(s)/letter(s) or waiver should be provided to the *FZM* in PDF format.

|  |  |
| --- | --- |
| **Copyrights** | [Top](http://www.eusjournal.com/contributors.asp#top) |

The entire contents of the Journal are protected under international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.

|  |  |
| --- | --- |
| **Checklist** | [Top](http://www.eusjournal.com/contributors.asp#top) |

**Covering letter**

* Signed by all contributors
* Previous publication / presentations mentioned
* Source of funding mentioned
* Conflicts of interest disclosed

**Authors**

* Last name and given name provided along with Middle name initials (where applicable)
* Author for correspondence, with e-mail address provided
* Number of contributors restricted as per the instructions
* Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as 'our study', names on figure labels, name of institute in photographs, etc.)

**Presentation and format**

* Double spacing
* Margins 2.5 cm from all four sides
* Page numbers included at bottom
* Title page contains all the desired information
* Running title provided (not more than 50 characters)
* Abstract page contains the full title of the manuscript
* Abstract provided (structured abstract of 250 words for original articles, unstructured abstracts of about 150 words for all other manuscripts excluding letters to the Editor)
* Key words provided (three or more)
* Introduction of 75-100 words
* Headings in title case (not ALL CAPITALS)
* The references cited in the text should be after punctuation marks, in superscript with square bracket.
* References according to the journal's instructions, punctuation marks checked
* Send the article file without ‘Track Changes’

**Language and grammar**

* Uniformly American English
* Write the full term for each abbreviation at its first use in the title, abstract, keywords and text separately unless it is a standard unit of measure. Numerals from 1 to 10 spelt out
* Numerals at the beginning of the sentence spelt out
* Check the manuscript for spelling, grammar and punctuation errors
* If a brand name is cited, supply the manufacturer's name and address (city and state/country).
* Species names should be in italics

**Tables and figures**

* No repetition of data in tables and graphs and in text
* Actual numbers from which graphs drawn, provided
* Figures necessary and of good quality (color)
* Table and figure numbers in Arabic letters (not Roman)
* Labels pasted on back of the photographs (no names written)
* Figure legends provided (not more than 40 words)
* Patients' privacy maintained (if not permission taken)
* Credit note for borrowed figures/tables provided
* Write the full term for each abbreviation used in the table as a footnote